Timothy Miller, MD, PhD, will be presenting late-breaking data during the ANA2021 plenary session "Advances in Amyotrophic Lateral Sclerosis," scheduled for Sunday, October 17 from 3:15 PM - 5:15 PM EDT. His presentation, "Antisense Oligonucleotide Therapy for SOD1 ALS," will include topline results from Biogen's pivotal Phase 3 VALOR study of tofersen (BIIB067), an investigational antisense oligonucleotide (ASO) drug being evaluated for people with superoxide dismutase 1 (SOD1) ALS.
Dr. Miller is the David Clayson Professor of Neurology at the School of Medicine at Washington University in St. Louis where he serves as the Principal Investigator on multiple clinical and research studies in addition to directing the ALS Center and the Miller Lab.
We hope you'll join us as Dr. Miller presents his groundbreaking research. You can access this presentation, and many more, by registering for ANA2021.